KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Current Deferred Revenue: 2011-2024

Historic Current Deferred Revenue for Rigel Pharmaceuticals (RIGL) over the last 13 years, with Dec 2024 value amounting to $1.4 million.

  • Rigel Pharmaceuticals' Current Deferred Revenue changed negligibly% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $1.4 million for FY2024, which is negligibly% changed negligibly from last year.
  • According to the latest figures from FY2024, Rigel Pharmaceuticals' Current Deferred Revenue is $1.4 million, which was down 0.00% from $1.4 million recorded in FY2023.
  • Over the past 5 years, Rigel Pharmaceuticals' Current Deferred Revenue peaked at $3.0 million during FY2020, and registered a low of $1.4 million during FY2023.
  • Over the past 3 years, Rigel Pharmaceuticals' median Current Deferred Revenue value was $1.4 million (recorded in 2024), while the average stood at $1.4 million.
  • Data for Rigel Pharmaceuticals' Current Deferred Revenue shows a maximum YoY plummeted of 88.07% (in 2020) over the last 5 years.
  • Over the past 5 years, Rigel Pharmaceuticals' Current Deferred Revenue (Yearly) stood at $3.0 million in 2020, then fell by 13.98% to $2.6 million in 2021, then slumped by 47.27% to $1.4 million in 2022, then declined by 1.02% to $1.4 million in 2023, then remained steady at $1.4 million in 2024.